Ramsey Cheung
Academic Appointments
- Professor - Med Center Line, Medicine - Gastroenterology & Hepatology
- Member, Stanford Cancer Institute
Key Documents
Contact Information
-
Clinical Offices
VA Palo Alto Health Care System 3801 Miranda Ave Palo Alto, CA 94304 Tel Work (650) 493-5000 Fax (650) 852-3259
- Academic Offices
Personal Information EmailNot for medical emergencies or patient use
Professional Overview
Clinical Focus
- Gastroenterology
- Hepatology (Liver)
Administrative Appointments
- Director, Fellowship in GI & Hepatology, Stanford (2004 - present)
- Chief of Hepatology, VAPAHCS (1999 - present)
- Associate Director, Fellowship in GI & Hepatology, Stanford (2002 - 2004)
- Director of Endoscopy, VAPAHCS (1997 - 1998)
- Chief of Gastroenterology, VA-Livermore (1993 - 1995)
Honors and Awards
- Teaching Award, Department of Medicine (2002, 2004, 2006, 2007)
Professional Education
| Fellowship: | Stanford University School of Medicine CA (1991) |
| Internship: | UCI College of Medicine CA (1983) |
| Medical Education: | University of Chicago School of Medicine IL (1982) |
| Board Certification: | Gastroenterology, American Board of Internal Medicine (1991) |
| Board Certification: | Internal Medicine, American Board of Internal Medicine (1986) |
Scientific Focus
Current Research Interests
Dr. Cheung's past research utilized the duck animal model to study the mechanism of viral neutralization of hepatitis B virus at the molecular level. In collaboration with basic scientists, he is interested in using molecular biology approaches to study clinical samples from chronic hepatitis C patients and investigate the host-virus interaction. The ultimate goal is to understand the pathogenesis of HCV and mechanism of anti-viral therapy. Dr. Cheung is also investigating the healthcare model of hepatitis C care among infected veterans, interaction between hepatitic C infection and alcoholic cirrhosis, and impact of comorbid conditions on the health related quality of life. He is investigating methods to improve care of veterans with chronic hepatitis C, including use of the novel experimental anti-viral therapies as part of clinical trails. Dr. Cheung also used VA and other database to study various healthcare issues in patients with chronic hepatitis C.
Clinical Trials
- Not Recruiting Study of Nitazoxanide, Peginterferon Alfa-2a and Ribavirin for the Treatment of Hepatitis C
- Not Recruiting Study of Nitazoxanide, Peginterferon Alfa-2a and Ribavirin in Treatment-Naive Hepatitis C Patients
- Not Recruiting Risk Factors and Molecular Genomics of U.S. Patients With Chronic Liver Disease &Hepatocellular CA
Publications
- The impact of chronic hepatitis C and co-morbid illnesses on health-related quality of life. Qual Life Res. 2008; (5): 715-24
- A 7 gene signature identifies the risk of developing cirrhosis in patients with chronic hepatitis C. Hepatology. 2007; (2): 297-306
- Incidence of statin hepatotoxicity in patients with hepatitis C. Clin Gastroenterol Hepatol. 2006; (7): 902-7; quiz 806
- Epidemiology of hepatitis C virus infection in American veterans. Am J Gastroenterol. 2000; (3): 740-7
- Assessment and utilization of rapid virologic response in US veterans with chronic hepatitis C: evaluating provider adherence to practice guidelines. J Clin Gastroenterol. 2013; (3): 264-70
- Implications of rapid virological response in hepatitis C therapy in the US veteran population. Aliment Pharmacol Ther. 2012; (1): 105-15
Help
Trial Administration